ARLINGTON, Va., May 6 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC:CSBR) (BULLETIN BOARD: CSBR) , a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, announced today the completion of a Service Agreement with Concordia Pharmaceuticals, Inc. and initiation of preclinical studies to evaluate new applications for Salirasib using Champions Biotechnology's Biomerk Tumorgrafts(TM). "Our Biomerk Tumorgraft preclinical platform and its benefits in drug discovery and evaluation is gaining recognition as we expand our platform to pharmaceutical and biotech companies" said Doug Burkett, Ph.D., President of Champions Biotechnology, Inc. "Champions is in a unique position to evaluate oncology drugs as well as novel drug combinations that may be effective in treating specific cancer types. We are pleased to be assisting Concordia Pharmaceuticals in the evaluation of new preclinical applications for Salirasib, a Ras-antagonist that acts to inhibit cancer by impairing the disease's ability to replicate defective cells." For more information regarding Champions Biotechnology's growing business and recent news, please visit http://www.championsbiotechnology.com/. About Champions Biotechnology, Inc. Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and predictive tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting xenografts (Biomerk Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. The Company believes that these Tumorgrafts closely reflect human cancer biology and their response to drugs is more predictive of clinical outcomes in cancer patients. Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates through pre-clinical trials. As drugs progress through this early stage of development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care. In the course of this process, this permits the Company to evaluate oncology drugs for companies by using models that integrate prognostic testing with biomarker discovery. Champions Biotechnology is dedicated to enhancing preclinical development tools, accelerating development and valuation of oncology drugs, and advancing personalized treatment with a goal to improve the lives of cancer patients globally. This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Biotechnology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Biotechnology's Form 10-KSB for the fiscal year ended April 30, 2007 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Biotechnology's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Biotechnology's expectations, except as required by law. DATASOURCE: Champions Biotechnology CONTACT: James Martell of Champions Biotechnology, +1-410-630-1313 Web site: http://www.championsbiotechnology.com/

Copyright